Minneapolis,  MN 
United States
  • Booth: 4421, S11, S12

Through innovation and collaboration, Medtronic improves the lives and health of millions of people each year. Our GI business is dedicated to patient-friendly innovations enabling early detection and treatment of chronic GI diseases and cancers. Our portfolio includes PillCam™ Capsule Endoscopy, Bravo™ Reflux Testing, ManoScan™ High Resolution Manometry, Barrx™ RF Ablation, Beacon™ EUS, Enterra™ Gastric Electrical Stimulation and Kangaroo™ enteral feeding pumps and access devices.


Medtronic GI Solutions


  • The PillCamTM Perspective

    A Virtual Reality Experience

    Start your Journey Booth 4421

 Press Releases

  • Medtronic Receives Expanded Indication From FDA for Pillcam(TM) Colon 2 Capsule

    March 31, 2016 7:30 AM CT

    Potentially Reaching More Patients at Risk for Colon Cancer

    DUBLIN - March 31, 2016 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug

    Administration (FDA) cleared PillCam(TM) COLON 2 capsule for an expanded indication for use. The PillCam(TM)

    COLON 2 capsule is the only non-invasive diagnostic test that directly visualizes the colon for the evaluation of polyps

    in patients who are at major risks for colonoscopy or moderate sedation. The PillCam(TM) capsule- a vitamin-sized

    capsule endoscope that is taken orally - does not require sedation, anesthesia or radiation, which makes it a more

    convenient procedure than other invasive colon exams.

    This expanded indication is for the detection of colon polyps in patients with evidence of gastrointestinal bleeding of

    lower gastrointestinal (Gl) origin. This applies only to patients with major risks for colonoscopy or moderate sedation,

    but who could tolerate colonoscopy and moderate sedation in the event a clinically significant colon abnormality was

    identified on capsule endoscopy.

    Colon cancer is the third most commonly diagnosed cancer and second leading cause of cancer death in both men and

    women combined in the U.S. An estimated 136,000 people will be diagnosed with colorectal cancer each year, but when it

    is caught at a localized stage, the overall 5-year survival rate is 90%.[i]

    According to Gastrointestinal Endoscopy, 14 million colonoscopiesare performed in the U.S. each year - of these, more

    than 3 million are performed for lower GI bleeding, and 600 thousand of those patients are at elevated risk for

    complications. [ii] [iii]

    "The ability to offer PillCam COLON capsule to an expanded patient group represents a significant breakthrough in GI

    healthcare," said Douglas Rex, M.D., Distinguished Professor of Medicine and Chancellor's Professor, Indiana University

    School of Medicine and Director of Endoscopy, IU Health University Hospital. "The new indication allows

    gastroenterologists to provide their at-risk patients with a non-invasive and radiation free alternative to traditional


    "We are committed to the early detection and treatment of chronic GI diseases and cancers. We are pleased with the FDA's

    decision to clear this expanded indication for PillCam(TM) COLON capsule which will provide access to more patients

    who can benefit from this technology," said Vafa Jamali, president, Early Technologies business in the Medtronic

    Minimally Invasive Therapies Group.

    PillCam(TM) COLON 2 capsule was previously cleared by the FDA for visualization of the colon and the detection of

    colon polyps in patients following an incomplete colonoscopy with adequate preparation, and a complete evaluation of

    the colon was not technically possible. The PillCam(TM) capsule technology may also limit the risk of complications that

    could occur from a standard colonoscopy, such as colon perforation, bleeding or cardio-pulmonary complications.


    A multimedia version of this release is available, including a downloadable photo.

    About Medtronic

    Medtronic plc (, headquartered in Dublin, Ireland, is among the world's largest medical technology,

    services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the

    Page 1/2

    world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in

    approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take

    healthcare Further, Together.

    Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's

    periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from

    anticipated results.


    [i] ACS Colorectal Cancer Facts & Figures 2014-2016;


    [ii] Leiberman D, et al. Colonoscopy utilization and outcomes 2000 to 2011. Gastrointestinal Endoscopy, 2014.

    [iii] Johnson D, Lieberman D, Pochapin M, et al. Occurrence of Delayed Non-GI Events Post-Colonoscopy and Patients

    with Identifiable Increased Risk [abstract]. Am J Gastroenterol 2014;109:S647.


  • Beacon FNF Pre-loaded Needle
    The Beacon™ FNF needle is pre-loaded with two solid gold fiducial markers and enables easy target visualization with simple and accurate fiducial placement.

  • HET Bipolar System
    The HET™ bipolar system is a proprietary technology that allows for the gentle, simple, and effective treatment of all symptomatic grades I and II hemorrhoids in a single procedure....
  • Barrx
    The Barrx™ radiofrequency ablation system facilitates a 360 degree, 3 cm long ablation for treating short and long segments of Barrett's epithelium.

  • Bravo Reflux Testing
    The Bravo™ reflux capsule is a device that attaches to the esophageal tissue to assess pH levels and transmits data to the recorder.

  • Optimize Reflux Patient Management With Advanced pH Monitoring

    The Bravo™ reflux testing system is an innovative capsule-based ambulatory pH test that captures esophageal pH data for up to 96 hours.

    • Extended 96-hour recording time provides four times the data compared to a 24-hour catheter-based test
    • Allows for the evaluation of patients off PPI therapy, which is clinically beneficial in patients with refractory GERD([FOOTNOTE=Garrean CP, et al. Acid Reflux Detection and Symptom-Reflux Association using 4-Day Wireless pH Recording Combining 48-Hour Periods Off and On PPI Therapy. Am J Gastroenterol. 2008;103:1631-1637. Page 1636, Col 2. ],[ANCHOR=],[LINK=])
    • Catheter-free design is better tolerated and preferred by patients2
    • Allows physicians to document relationships between symptoms and acid reflux events4

  • PillCam SB3 Capsule
    A camera inside a capsule that captures images at a frame rate of 2 to 6 frames per second (fps) based on capsule speed as it travels through the small bowel.

  • The PillCam™ SB 3 system allows for direct visualization of the small bowel, supporting greater confidence when monitoring lesions3 that may be related to Crohn’s disease, obscure bleeding, or iron deficiency anemia. The system features advanced optics and imaging designed to deliver exceptional images of the mucosa.

    This system includes innovative features like adaptive frame rate technology, which supports image acquisition that is uniquely suited to each patient's motility, as well as the tools you need to record and interpret study results. The software contains our most advanced algorithms, providing you with the tools you need to efficiently read and interpret study results.

 Additional Info

DDW Tracks
Inflammatory Bowel Diseases, Esophageal Diseases, Stomach and Small Bowel Disorders, Colorectal Diseases, Technologies and Procedural Innovations
Does your company only service US attendees?

Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".


For Marketing Opportunities offered by our partner TriStar, click here